J. S. Chua, H. J. Baelde, and M. Zandbergen, Complement factor C4d is a common denominator in thrombotic microangiopathy, J Am Soc Nephrol, vol.26, pp.2239-2247, 2015.
DOI : 10.1681/asn.2014050429
URL : https://jasn.asnjournals.org/content/26/9/2239.full.pdf

M. C. Pickering, D. 'agati, V. D. Nester, and C. M. , C3 glomerulopathy: consensus report, vol.84, pp.1079-1089, 2013.
DOI : 10.1038/ki.2013.377
URL : https://doi.org/10.1038/ki.2013.377

J. Hou, G. S. Markowitz, and A. S. Bomback, Toward a working definition of C3 glomerulopathy by immunofluorescence, Kidney Int, vol.85, pp.450-456, 2014.

C. P. Larsen, J. M. Ambuzs, and S. M. Bonsib, Membranous-like glomerulopathy with masked IgG kappa deposits, Kidney Int, vol.86, pp.154-161, 2014.
DOI : 10.1038/ki.2013.548

C. P. Larsen, N. C. Messias, and P. D. Walker, Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits, Kidney Int, vol.88, pp.867-873, 2015.
DOI : 10.1038/ki.2015.195
URL : https://doi.org/10.1038/ki.2015.195

H. T. Cook, C4d staining in the diagnosis of C3 glomerulopathy, J Am Soc Nephrol, vol.26, pp.2609-2611, 2015.

S. Sethi, S. H. Nasr, D. Vriese, and A. S. , C4d as a diagnostic tool in proliferative GN, J Am Soc Nephrol, vol.26, pp.2852-2859, 2015.

C. D. West, D. P. Witte, and A. J. Mcadams, Composition of nephritic factorgenerated glomerular deposits in membranoproliferative glomerulonephritis type 2, Am J Kidney Dis, vol.37, pp.1120-1130, 2001.

S. Sethi, F. C. Fervenza, and Y. Zhang, C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up, Kidney Int, vol.82, pp.465-473, 2012.
DOI : 10.1038/ki.2012.212
URL : https://doi.org/10.1038/ki.2012.212

S. Sethi, J. D. Gamez, and J. A. Vrana, Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway, Kidney Int, vol.75, pp.952-960, 2009.

C. Loirat, F. Fakhouri, and G. Ariceta, An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, vol.31, pp.15-39, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02149335

J. Caprioli, M. Noris, and S. Brioschi, Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome, Blood, vol.108, pp.1267-1279, 2006.

D. Kavanagh, T. H. Goodship, and A. Richards, Atypical hemolytic uremic syndrome, Semin Nephrol, vol.33, pp.508-530, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01793663

F. H. Sansbury, H. J. Cordell, and C. Bingham, Factors determining penetrance in familial atypical haemolytic uraemic syndrome, J Med Genet, vol.51, pp.756-764, 2014.

E. Bresin, E. Rurali, and J. Caprioli, Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, vol.24, pp.475-486, 2013.

M. Noris and G. Remuzzi, Hemolytic uremic syndrome, J Am Soc Nephrol, vol.16, pp.1035-1050, 2005.
URL : https://hal.archives-ouvertes.fr/hal-01793663

A. Servais, L. H. Noel, and L. T. Roumenina, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-464, 2012.

F. C. Fervenza, R. J. Smith, and S. Sethi, Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis, Am J Kidney Dis, vol.60, pp.126-132, 2012.

G. Sandhu, A. Bansal, and A. Ranade, C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis, Am J Kidney Dis, vol.60, pp.1039-1043, 2012.
DOI : 10.1053/j.ajkd.2012.04.032

K. A. Vernon, G. De-jorge, E. Hall, and A. E. , Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency, Am J Kidney Dis, vol.60, pp.121-125, 2012.

Y. Yu, M. P. Triebwasser, and E. K. Wong, Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration, Hum Mol Genet, vol.23, pp.5283-5293, 2014.

D. Kavanagh, Y. Yu, and E. C. Schramm, Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels, Hum Mol Genet, vol.24, pp.3861-3870, 2015.

S. Recalde, A. Tortajada, and M. Subias, Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases, J Am Soc Nephrol, vol.27, pp.1305-1311, 2016.

A. Misra, A. Peethambaram, and A. Garg, Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature, Medicine (Baltimore), vol.83, pp.18-34, 2004.

L. A. Dalvin, F. C. Fervenza, S. Sethi, and J. S. Pulido, Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III, Retin Cases Brief Rep, vol.10, pp.72-78, 2016.

J. Duvall-young, M. K. Macdonald, and N. M. Mckechnie, Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report, Br J Ophthalmol, vol.73, pp.297-302, 1989.

P. W. Mathieson, R. Wurzner, and D. B. Oliveria, Complement-mediated adipocyte lysis by nephritic factor sera, J Exp Med, vol.177, pp.1827-1831, 1993.
DOI : 10.1084/jem.177.6.1827
URL : http://jem.rupress.org/content/177/6/1827.full.pdf

L. G. Fritsche, W. Chen, and M. Schu, Seven new loci associated with age-related macular degeneration, Nat Genet, vol.45, pp.433-439, 2013.

A. Gerber, H. Karch, and F. Allerberger, Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolyticuremic syndrome in pediatric patients, Germany and Austria: a prospective study, vol.186, pp.493-500, 1997.

A. Angioi, F. C. Fervenza, and S. Sethi, Diagnosis of complement alternative pathway disorders, Kidney Int, vol.89, pp.278-288, 2016.

J. Zuber, F. Fakhouri, and L. T. Roumenina, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-657, 2012.

F. Bu, N. G. Borsa, and M. B. Jones, High-Throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies, J Am Soc Nephrol, vol.27, pp.1245-1253, 2016.
DOI : 10.1681/asn.2015040385
URL : https://jasn.asnjournals.org/content/27/4/1245.full.pdf

S. R. De-cordoba, Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations, Immunobiology, vol.221, pp.709-714, 2016.

M. Noris, S. Brioschi, and J. Caprioli, Familial haemolytic uraemic syndrome and an MCP mutation, Lancet, vol.362, pp.1542-1547, 2003.
DOI : 10.1016/s0140-6736(03)14742-3

A. Richards, E. J. Kemp, and M. K. Liszewski, Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome, Proc Natl Acad Sci, vol.100, pp.12966-12971, 2003.

B. H. Ault, B. Z. Schmidt, and N. L. Fowler, Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism, J Biol Chem, vol.272, pp.25168-25175, 1997.
DOI : 10.1074/jbc.272.40.25168
URL : http://www.jbc.org/content/272/40/25168.full.pdf

M. Levy, L. Halbwachs-mecarelli, and M. C. Gubler, H deficiency in two brothers with atypical dense intramembranous deposit disease, Kidney Int, vol.30, pp.949-956, 1986.

R. Martinez-barricarte, M. Heurich, and F. Valdes-canedo, Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation, J Clin Invest, vol.120, pp.3702-3712, 2010.

T. Montes, G. De-jorge, E. Ramos, and R. , Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis, Mol Immunol, vol.45, pp.2897-2904, 2008.

L. Schejbel, I. M. Schmidt, and M. Kirchhoff, Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation, Genes Immun, vol.12, pp.90-99, 2011.

C. Abarrategui-garrido, R. Martinez-barricarte, and M. Lopez-trascasa, Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome, Blood, vol.114, pp.4261-4271, 2009.

M. Delvaeye, M. Noris, D. Vriese, and A. , Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.345-357, 2009.

V. Fremeaux-bacchi, F. Fakhouri, and A. Garnier, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-562, 2013.

M. Lemaire, V. Fremeaux-bacchi, and F. Schaefer, Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, pp.531-536, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01064383

T. K. Maga, C. J. Nishimura, and A. E. Weaver, Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome, Hum Mutat, vol.31, pp.1445-1460, 2010.

M. Noris and G. Remuzzi, Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-1687, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01793663

J. Esparza-gordillo, G. De-jorge, E. Buil, and A. , Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32, Hum Mol Genet, vol.14, pp.703-712, 2005.

R. C. Challis, G. S. Araujo, and E. K. Wong, A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.27, pp.1617-1624, 2016.

Q. Chen, M. Wiesener, and H. U. Eberhardt, Complement factor H-related hybrid protein deregulates complement in dense deposit disease, J Clin Invest, vol.124, pp.145-155, 2014.

D. P. Gale, E. G. De-jorge, and H. T. Cook, Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis, Lancet, vol.376, pp.794-801, 2010.

A. Tortajada, H. Yebenes, and C. Abarrategui-garrido, C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation, J Clin Invest, vol.123, pp.2434-2446, 2013.
DOI : 10.1172/jci68280
URL : http://europepmc.org/articles/pmc3668852?pdf=render

E. Valoti, M. Alberti, and A. Tortajada, A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation, J Am Soc Nephrol, vol.26, pp.209-219, 2015.
DOI : 10.1681/asn.2013121339
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279739/pdf

J. P. Venables, L. Strain, and D. Routledge, Atypical haemolytic uraemic syndrome associated with a hybrid complement gene, PLoS Med, vol.3, p.431, 2006.

Y. Athanasiou, K. Voskarides, and D. P. Gale, Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees, Clin J Am Soc Nephrol, vol.6, pp.1436-1446, 2011.

S. Chauvet, L. T. Roumenina, and S. Bruneau, A familial C3GN secondary to defective C3 regulation by complement receptor 1 and factor H, J Am Soc Nephrol, vol.27, pp.1665-1677, 2016.
DOI : 10.1681/asn.2015040348
URL : https://hal.archives-ouvertes.fr/inserm-02149496

M. Noris and G. Remuzzi, Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation, Curr Opin Nephrol Hypertens, vol.22, pp.704-712, 2013.
DOI : 10.1097/mnh.0b013e328365b3fe

S. Richards, N. Aziz, and S. Bale, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, vol.17, pp.405-424, 2015.

M. Frimat, F. Tabarin, and J. D. Dimitrov, Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome, Blood, vol.122, pp.282-292, 2013.

J. E. Goicoechea-de, C. L. Harris, and J. Esparza-gordillo, Gain-offunction mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proc Natl Acad Sci, vol.104, pp.240-245, 2007.

T. Manuelian, J. Hellwage, and S. Meri, Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome, J Clin Invest, vol.111, pp.1181-1190, 2003.

M. C. Marinozzi, L. Vergoz, and T. Rybkine, Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?, J Am Soc Nephrol, vol.25, pp.2053-2065, 2014.

M. Noris, M. Galbusera, and S. Gastoldi, Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1726, 2014.

D. Perez-caballero, C. Gonzalez-rubio, and M. E. Gallardo, Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome, Am J Hum Genet, vol.68, pp.478-484, 2001.

L. T. Roumenina, M. Jablonski, and C. Hue, Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome, Blood, vol.114, pp.2837-2845, 2009.

P. Sanchez-corral, D. Perez-caballero, and O. Huarte, Structural and functional characterization of factor H mutations associated with THJ, Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference report

, atypical hemolytic uremic syndrome, Kidney International, vol.91, pp.1285-1295, 2002.

E. C. Schramm, L. T. Roumenina, and T. Rybkine, Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome, Blood, vol.125, pp.2359-2369, 2015.
DOI : 10.1182/blood-2014-10-609073
URL : http://www.bloodjournal.org/content/125/15/2359.full.pdf

A. L. Stahl, F. Vaziri-sani, and S. Heinen, Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation, Blood, vol.111, pp.5307-5315, 2008.

M. E. Bernabeu-herrero, M. Jimenez-alcazar, and J. Anter, Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome, Mol Immunol, vol.67, pp.276-286, 2015.

J. Caprioli, F. Castelletti, and S. Bucchioni, Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease, Hum Mol Genet, vol.12, pp.3385-3395, 2003.

C. L. Harris, M. Heurich, and S. Rodriguez-de-cordoba, The complotype: dictating risk for inflammation and infection, Trends Immunol, vol.33, pp.513-521, 2012.

M. C. Pickering, E. G. De-jorge, and R. Martinez-barricarte, Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains, J Exp Med, vol.204, pp.1249-1256, 2007.
DOI : 10.1084/jem.20070301
URL : http://europepmc.org/articles/pmc2118613?pdf=render

M. Noris, J. Caprioli, and E. Bresin, Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010.

D. Sanchez-chinchilla, S. Pinto, and B. Hoppe, Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.9, pp.1611-1619, 2014.

M. A. Abrera-abeleda, C. Nishimura, and K. Frees, Allelic variants of complement genes associated with dense deposit disease, J Am Soc Nephrol, vol.22, pp.1551-1559, 2011.
DOI : 10.1681/asn.2010080795
URL : https://jasn.asnjournals.org/content/22/8/1551.full.pdf

T. D. Barbour, M. M. Ruseva, and M. C. Pickering, Update on C3 glomerulopathy, Nephrol Dial Transplant, vol.31, pp.717-725, 2016.
DOI : 10.1093/ndt/gfu317
URL : https://academic.oup.com/ndt/article-pdf/31/5/717/6838133/gfu317.pdf

J. E. Goicoechea-de, J. J. Caesar, and T. H. Malik, Dimerization of complement factor H-related proteins modulates complement activation in vivo, Proc Natl Acad Sci U S A, vol.110, pp.4685-4690, 2013.

C. Licht, S. Heinen, and M. Jozsi, Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II), Kidney Int, vol.70, pp.42-50, 2006.

E. K. Wong, H. E. Anderson, and A. P. Herbert, Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN, J Am Soc Nephrol, vol.25, pp.2425-2433, 2014.

C. M. Legendre, C. Licht, and P. Muus, Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.368, pp.2169-2181, 2013.

P. M. Mannucci and M. Cugno, The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring, Thromb Res, vol.136, pp.851-854, 2015.

R. L. Donne, I. Abbs, and P. Barany, Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor, Am J Kidney Dis, vol.40, p.22, 2002.

H. Povey, R. Vundru, and N. Junglee, Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis, Clin Nephrol, vol.82, pp.326-331, 2014.

P. Tarshish, J. Bernstein, and J. N. Tobin, Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone-a report of the International Study of Kidney Disease in Children, Pediatr Nephrol, vol.6, pp.123-130, 1992.

C. Licht, L. A. Greenbaum, and P. Muus, Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, vol.87, pp.1061-1073, 2015.

R. Coppo, R. Bonaudo, and R. L. Peruzzi, Liver transplantation for aHUS: still needed in the eculizumab era?, Pediatr Nephrol, vol.31, pp.759-768, 2016.

C. Rabasco, T. Cavero, and E. Roman, Effectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney Int, vol.88, pp.1153-1160, 2015.

N. Besbas, B. Gulhan, and S. Gucer, A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl, J Nephrol, vol.27, pp.457-460, 2014.

A. S. Bomback, R. J. Smith, and G. R. Barile, Eculizumab for dense deposit disease and C3 glomerulonephritis, Clin J Am Soc Nephrol, vol.7, pp.748-756, 2012.
DOI : 10.2215/cjn.12901211
URL : https://cjasn.asnjournals.org/content/7/5/748.full.pdf

D. Bonucchi, M. Leonelli, and F. Damiano,

, G Ital Nefrol, vol.27, pp.82-84, 2010.

E. Daina, M. Noris, and G. Remuzzi, Eculizumab in a patient with densedeposit disease, N Engl J Med, vol.366, pp.1161-1163, 2012.

A. S. Garnier, J. F. Augusto, and I. Pellier, Successful long-term outcome of kidney transplantation in a patient with X-linked thrombocytopenia: 9-year follow-up, Transplantation, vol.98, pp.57-58, 2014.

S. Gurkan, B. Fyfe, and L. Weiss, Eculizumab and recurrent C3 glomerulonephritis, Pediatr Nephrol, vol.28, pp.1975-1981, 2013.
DOI : 10.1007/s00467-013-2503-y
URL : http://europepmc.org/articles/pmc4428658?pdf=render

L. C. Herlitz, A. S. Bomback, and G. S. Markowitz, Pathology after eculizumab in dense deposit disease and C3 GN, J Am Soc Nephrol, vol.23, pp.1229-1237, 2012.

M. Inman, G. Prater, and H. Fatima, Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis, Clin Kidney J, vol.8, pp.445-448, 2015.

E. Kerns, D. Rozansky, and M. L. Troxell, Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy, Pediatr Nephrol, vol.28, pp.2227-2231, 2013.

L. Quintrec, M. Lionet, A. Kandel, and C. , Eculizumab for treatment of rapidly progressive C3 glomerulopathy, Am J Kidney Dis, vol.65, pp.484-489, 2015.

J. A. Mccaughan, D. M. O'rourke, and A. E. Courtney, Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies, Am J Transplant, vol.12, pp.1046-1051, 2012.

M. J. Oosterveld, M. R. Garrelfs, and B. Hoppe, Eculizumab in pediatric Dense Deposit Disease, Clin J Am Soc Nephrol, vol.10, pp.1773-1782, 2015.

O. Ozkaya, H. Nalcacioglu, and D. Tekcan, Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy, Pediatr Nephrol, vol.29, pp.1283-1287, 2014.

S. Radhakrishnan, A. Lunn, and M. Kirschfink, Eculizumab and refractory membranoproliferative glomerulonephritis, N Engl J Med, vol.366, pp.1165-1166, 2012.
DOI : 10.1056/nejmc1106619

C. Rousset-rouviere, M. Cailliez, and F. Garaix, Rituximab fails where eculizumab restores renal function in C3nef-related DDD, Pediatr Nephrol, vol.29, pp.1107-1111, 2014.

A. Sanchez-moreno, F. De-la-cerda, and R. Cabrera, Eculizumab in densedeposit disease after renal transplantation, Pediatr Nephrol, vol.29, pp.2055-2059, 2014.

M. Vivarelli, A. Pasini, and F. Emma, Eculizumab for the treatment of densedeposit disease, N Engl J Med, vol.366, pp.1163-1165, 2012.

S. J. Barbour, G. Espino-hernandez, and H. N. Reich, The MEST score provides earlier risk prediction in lgA nephropathy, Kidney Int, vol.89, pp.167-175, 2016.

D. C. Cattran, R. Coppo, and H. T. Cook, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification, Kidney Int, vol.76, pp.534-545, 2009.

I. S. Roberts, H. T. Cook, and S. Troyanov, The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility, Kidney Int, vol.76, pp.546-556, 2009.

N. Amornsiripanitch, S. Hong, and M. J. Campa, Complement factor H autoantibodies are associated with early stage NSCLC, Clin Cancer Res, vol.16, pp.3226-3231, 2010.
DOI : 10.1158/1078-0432.ccr-10-0321
URL : http://clincancerres.aacrjournals.org/content/16/12/3226.full.pdf

M. A. Dragon-durey, S. K. Sethi, and A. Bagga, Clinical features of antifactor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-2187, 2010.

P. Khandelwal, A. Gupta, and A. Sinha, Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome, Pediatr Nephrol, vol.30, pp.451-457, 2015.

A. Sinha, A. Gulati, and S. Saini, Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children, Kidney Int, vol.85, pp.1151-1160, 2014.

N. S. Sheerin, D. Kavanagh, and T. H. Goodship, A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, QJM, vol.109, pp.27-33, 2016.

J. F. Wetzels and N. C. Van-de-kar, Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.65, p.342, 2015.

. Thj-goodship, aHUS and C3 glomerulopathy: a KDIGO conference report

G. Ardissino, I. Possenti, and F. Tel, Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update, Am J Kidney Dis, vol.66, pp.172-173, 2015.

G. Ardissino, S. Testa, and I. Possenti, Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases, Am J Kidney Dis, vol.64, pp.633-637, 2014.

C. E. Alpers, B. Usa;-gerald, . Appel, . Usa;-gianluigi, I. Ardissino et al.,

M. Blasco and . Spain,

L. Burke, D. Usa;-thomas, . Cairns, . Uk;-mireya, . Carratala et al.,

D. Vivette, . D'agati, R. Usa;-mohamed, and . Daha, The Netherlands; An S

D. P. Gale, . Uk;-hermann, G. Haller, U. Johnson, . Józsi et al.,

M. M. O'shaughnessy, . Usa;-marion, F. Rabant, F. Rondeau, . Ruggenenti et al.,

. Thj-goodship, aHUS and C3 glomerulopathy: a KDIGO conference report

, Kidney International, vol.91, pp.539-551, 2017.